Furthermore, LCP2 was involved in some immune-responses-related signaling pathways and high expression of LCP2 increased the infiltration of anti-tumor immune cells and thus helped to predict the progression-free survival of patients with metastatic skin cutaneous melanoma receiving anti-PD-1 immunotherapy. The gene discussed is PDCD1; the disease is neoplasm.